^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    idetrexed (CT900)

    i
    Other names: CT900 , ONX 0801, BGC 945, BTG945
    Company:
    Algok Bio, Boston Scientific, Carrick Therap
    Drug class:
    Folate receptor 1 inhibitor
    Related drugs:
    over4years
    [VIRTUAL] A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer. (ASCO 2020)
    Four expansion cohorts were studied which included: schedule A (6 mg/m2/q every 2 weeks), schedule B (12 mg/m2/q every 2 weeks), schedule C (12 mg/m2/q every 2 weeks with 12 mg dexamethasone IV and 8 mg of dexamethasone for 2 days) and schedule D (12 mg/m2/q every 3 weeks)... CT900 has shown clinical activity in patients with heavily pre-treated platinum-resistant, high/medium FRα expressing HGSOC. Based on toxicity and efficacy, the schedule of 12 mg/m2/q2 weekly (schedule B) is the recommended phase II dose for further evaluation in patients with relapsed high/medium FRα expressing HGSOC. Research Funding: Carrick Therapeutics;BTG; Onyx
    Clinical • P1 data
    |
    FOLR1 ( Folate receptor alpha )
    |
    dexamethasone • idetrexed (CT900)